Abiomed touts positive new data from halted trial of Impella 2.5 pump
This article was originally published in Clinica
Executive Summary
Further analyses of data from the PROTECT II study of Abiomed's Impella 2.5 heart pump show that it reduces adverse events compared with an intra-aortic balloon (IAB) pump.